Egrifta (Tesamorelin) Storage, Stability & Shelf Life
HealthRX.com
Egrifta SV and WR have different mixing and discard rules
Key numbers
- 1.4 mgEgrifta SV dose per injection, given immediately after reconstitution (0.35 mL)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.28 mgEgrifta WR dose per injection, one of 7 daily doses (0.16 mL) from one reconstituted vialSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 7 daysEgrifta WR unused reconstituted solution must be discarded this many days after mixingSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 11.6 mgEgrifta WR vial strength, a formulation that is not substitutable with Egrifta SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Forms / Egrifta SV 2 mg vial; Egrifta WR 11.6 mg vial [1][2]
- SV dose / 1.4 mg (0.35 mL) once daily subcutaneously [1]
- WR dose / 1.28 mg (0.16 mL) once daily subcutaneously [2]
- SV after mixing / administer immediately; discard unused solution and diluent [1]
- WR after mixing / 7 daily doses; discard 7 days after mixing [2]
- Substitutable / No [2]
Which Egrifta do you have?
Egrifta SV is the 2 mg per vial formulation and Egrifta WR is the 11.6 mg per vial formulation [1][2]. Both are given once daily by subcutaneous injection into the abdomen, rotating sites [1][2]. The WR label states the two are not substitutable and differ in dosage, vials per dose, reconstitution and storage [2]. Older dosing information may refer to the original 1 mg-per-vial Egrifta formulation used in the pivotal trials [1].
Egrifta SV: mix, inject, discard
The Egrifta SV label says to reconstitute one vial with 0.5 mL of the supplied Sterile Water for Injection, mix by rolling the vial gently in your hands for 30 seconds rather than shaking, inspect for particulate matter and discoloration, and use only if the solution is clear, colorless and particle-free. The label says to administer 0.35 mL (1.4 mg) immediately after reconstitution and discard any unused solution and diluent [1].
Egrifta WR: one vial, seven doses, seven days
The Egrifta WR label says to reconstitute the 11.6 mg vial with 1.3 mL of the supplied Bacteriostatic Water for Injection, USP; move the vial in a circle to swirl the powder into the liquid rather than shaking, and use only if the solution is clear, colorless and free of particulate matter. One reconstituted vial provides 7 daily doses of 0.16 mL (1.28 mg), and the label says unused solution is discarded 7 days after mixing [2].
What people on Reddit report
Accounts from people using tesamorelin who ask whether a reconstituted vial can be kept past the labeled window, and whether it should be refrigerated or kept at room temperature.
I've used reconstituted tesa way past a week and I didn't grow an extra arm or anything. You'll be fine.Read the source discussion
I don't understand why people insist on storing at room temperature.Read the source discussion
I've been a part of degradation testing for Tesa, room temp vs. fridge over a 28 day period with 4 intervals. Minimal degradation for both so depending on your risk tolerance do what you will with this information.Read the source discussion
Questions worth asking
Compounded tesamorelin is a different product
Compounded tesamorelin is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before marketing [3]. FDA has made no category-based statement about compounding tesamorelin, and it is not on FDA's list of bulk substances that may present significant safety risks when compounded [4]. The mixing and discard instructions above come from the Egrifta SV and Egrifta WR labels and describe those products [1][2].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
How long is Egrifta good after mixing?
Can Egrifta SV and Egrifta WR be handled the same way?
Should the vial be shaken to dissolve the powder?
Does the same in-use limit apply to compounded tesamorelin?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- U.S. Department of Health and Human Services. Draft enforcement-discretion policy for compounding peptides, Appendix B. HHS peptide enforcement-discretion policy, Appendix B
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Reddit participants. Egrifta WR storage (r/Biohacking). Accessed 2026-11-10.
- Reddit participants. Tesamorelin room temp (r/PeptidePathways). Accessed 2026-11-10.